In conclusion, the preclinical and clinical data for the CD200R agonist ucenprubart demonstrate that targeting the immune checkpoint inhibitory receptor CD200R provides opportunities for durable treatment of autoimmune or inflammatory diseases such as AD. The gene discussed is CD200R1; the disease is Alzheimer disease.